Movano completes its second glucose pilot study

Pleasanton, calif., feb. 17, 2022 /prnewswire/ -- movano inc. (nasdaq:move), a health technology company designing devices that inspire and empower you to live a healthier, happier life, today announced the completion of an institutional review board (irb)-approved glucose pilot study, which was conducted on 10 participants with type 1 diabetes of varying gender, age, ethnicity and weight in conjunction with an independent fda-compliant clinical lab.
MOVE Ratings Summary
MOVE Quant Ranking